BioVersys AG (BIOV.SW)
Swiss · CHF · Healthcare · Biotechnology
CHF 24.50 (-0.81%) as of
Key statistics
- Market cap
- 143.44M
- Forward P/E
- -4.27
- EPS (TTM)
- -4.50
- Dividend yield
- 0.00%
- 52-week range
- 21.20 – 30.70
- Revenue (TTM)
- 4.62M
- Profit margin
- 0.00%
- Analyst target
- CHF 65.80
- Volume
- 3.31k
About BioVersys AG
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Basel, Switzerland
- Employees
- 38
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.